Ultime notizie per HMC Capital (OTC:HMCLF) Azioni

HMC Capital Ltd is a property group focused on ownership, development, and management. The company's operating segment includes Real Estate which comprises of HMC Capital managed HomeCo Daily Needs REIT, HealthCo Healthcare and Wellness REIT, HMC Wholesale Healthcare Fund and the Last Mile Logistics Fund; Private Equity which includes the HMC Capital Partners Fund I, a high conviction strategic stakes fund; and Corporate properties which includes unallocated costs and Capital Solutions activities which includes short term investments undertaken relating to non-HMC managed funds. It generates maximum revenue from the Real Estate segment. The company portfolio comprises mainly retail and services centers.

HOME CONSORTIUM LTD by HOME CONSORTIUM LTD.

HMC Capital Ltd

WIIM

MGNX

MacroGenics shares are trading higher after the company reported better-than-expected Q3 financial results.

News

Guidance

International Flavors & Fragrances Sees FY24 Sales $11.3B-$11.4B Vs $11.288B Est.

–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real World Study Compared Over 150,000 Adult &amp; Pediatric Patients – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor Associated with Fewer Adverse Drug Reactions – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor also Improved Healthcare Utilization –
NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations. The study, published in Frontiers of Pain Research, provides compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions (ADRs) and improved healthcare utilizations when compared to ketorolac.
This extensive, retrospective, payer database analysis evaluated the records of over 17 million patients who had received either ketorolac or Caldolor. Ultimately, 31,046 Caldolor and 124,184 ketorolac adult patients were selected and compared for ADRs and subsequent healthcare resource utilization, which includes inpatient, outpatient and emergency department visits as well as all procedures and prescriptions during the follow up time of 29 days. An additional 5,579 pediatric patients were identified in each arm and compared in a separate claims analysis.
Key findings reveal that, in adults, Caldolor was associated with a 45% reduction in renal dysfunction (p&lt;0.001) and a 78% decrease in hematuria rates (p&lt;0.001) when compared to ketorolac. Notably, patients also experienced fewer gastrointestinal complications as well as reduced headaches, nausea and abdominal pain. Among pediatric patients, the results showed Caldolor was associated with a 51-65% lower rate of ADRs, including headache and nausea, with 95% confidence intervals supporting clinical significance.
Caldolor also demonstrated a positive impact on healthcare resource utilization (HCRU) when compared to ketorolac, with decreased emergency room and outpatient visits, as well as a shortened hospital length of stay for both adults and children.

Biotech

General

CPIX

Cumberland Pharmaceuticals Announces The Publication Of New Real-World Outcomes Research Demonstrating The Safety And Healthcare Resource Advantages Of Its Caldolor (Ibuprofen) Injection Over Ketorolac In Both Adult And Pediatric Populations

AVNW

Aviat Networks shares are trading lower after the company reported worse-than-expected Q1 financial results and lowered its FY25 sales guidance.

Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) affirms FY2024 Adj EPS guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 analyst estimate. Affirms FY2024 sales outlook from $425.00 million-435.00 million to $425.00 million-435.00 million vs $430.33 million estimate.

FORR

Forrester Res Affirms FY2024 Adj EPS Guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 Est; Affirms FY2024 Sales Guidance from $425.00M-435.00M to $425.00M-435.00M vs $430.33M Est.

Sixth Street Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) reported quarterly earnings of $0.57 per share which met the analyst consensus estimate. This is a 5 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $119.223 million which beat the analyst consensus estimate of $118.508 million by 0.60 percent. This is a 4.18 percent increase over sales of $114.435 million the same period last year.

Earnings

Earnings Beats

TSLX

Sixth Street Specialty Q3 2024 Adj. EPS $0.57, Inline, Sales $119.223M Beat $118.508M Estimate

Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) reported quarterly earnings of $0.84 per share. This is a 14.29 percent decrease over earnings of $0.98 per share from the same period last year. The company reported $74.33 million in sales this quarter. This is a 11.67 percent decrease over sales of $84.15 million the same period last year.

WEYS

Weyco Group Q3 EPS $0.84 Down From $0.98 YoY, Sales $74.33M Down From $84.15M YoY

Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) reported quarterly earnings of $1.04 per share which missed the analyst consensus estimate of $1.08 by 3.7 percent. The company reported quarterly sales of $2.92 billion which beat the analyst consensus estimate of $2.83 billion by 3.29 percent. This is a 3.72 percent increase over sales of $2.82 billion the same period last year.

Earnings Misses

Intl Flavors & Fragrances Q3 2024 Adj EPS $1.04 Misses $1.08 Estimate, Sales $2.92B Beat $2.83B Estimate

Weyco Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) (the "Company") announced that today its Board of Directors declared a special one-time cash dividend of $2.00 per share, for a total of approximately $19.0 million based on the number of shares currently outstanding. The dividend will be paid on January 2, 2025, to shareholders of record at the close of business on November 18, 2024.

Dividends

Weyco Group Declares Special Cash Dividend Of $2.00 Per Share, For A Total Of ~$19M Based On The Number Of Shares Currently Outstanding

Offerings

PLBY

Playboy Announced The Closing Of Its Sale Of 14.9M Newly Issued Shares In A Private Placement At A Price Of $1.50 Per Share For A Total Purchase Price Of $22.35M

SMCI

Super Micro Computer shares are trading lower after the company lowered its financial outlook.

MCHP

Microchip Sees Q3 2024 Adj. EPS $0.29-$0.32

Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) lowers FY2024 Adj EPS guidance from $2.25-2.45 to $2.10-2.20 vs $2.26 analyst estimate. Lowers FY2024 sales outlook from $825.00 million-840.00 million to $800.00 million-805.00 million vs $824.37 million estimate.

HLIO

Helios Technologies Lowers FY2024 Adj EPS Guidance from $2.25-2.45 to $2.10-2.20 vs $2.26 Est; Lowers FY2024 Sales Guidance from $825.00M-840.00M to $800.00M-805.00M vs $824.37M Est

MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.20 by 10 percent. The company reported quarterly sales of $797.000 million which beat the analyst consensus estimate of $794.160 million by 0.36 percent. This is a 10.25 percent decrease over sales of $888.000 million the same period last year.

MRC Global Q3 2024 Adj. EPS $0.22 Beats $0.20 Estimate, Sales $797.000M Beat $794.160M Estimate

Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) lowers FY2024 GAAP EPS guidance from $1.35-1.55 to $1.15-1.25 vs $1.41 analyst estimate..

Helios Technologies Lowers FY2024 GAAP EPS Guidance from $1.35-1.55 to $1.15-1.25 vs $1.41 Est

Supermicro Sees Q2 FY2025 Net Sales $5.5B-$6.1B, GAAP EPS $0.48-$0.58, Non-GAAP EPS $0.56-$0.65

Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. This is unchanged from the same period last year. The company reported quarterly sales of $150.50 million which missed the analyst consensus estimate of $152.30 million by 1.18 percent. This is a 6.40 percent decrease over sales of $160.78 million the same period last year.

SWIM

Latham Group Q3 EPS $0.05 Misses $0.06 Estimate, Sales $150.50M Miss $152.30M Estimate

QLYS

Qualys Raises 2024 Adj EPS Guidance From $5.46- $5.62 To $5.81 - $5.91 (Est $5.57), Lifts Revenue Guidance From $597.5M - $601.5M To $602.9M - $605.9M (Est $599.362M)

InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) affirms FY2025 sales outlook from $815.00 million-865.00 million to $815.00 million-865.00 million.

Comments

HMC Capital

Notizie

Ultime notizie per HMC Capital (OTC:HMCLF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO